【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]Celltrion Files for Australian Approval of Cosentyx Biosimilar

온카뱅크관리자

2026-11-12 09:47:25

Besequma filings expand to five major markets PK equivalence confirmed in 172 healthy adults Targets $6.67 billion global Cosentyx market 
 <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="77yjHtB3mW">
 <figure class="figure_frm origin_fig" contents-hash="0f9e77a7b5aa0558563c6226687905e379c093669af4a18678bb1ca1dd8b1a0a" dmcf-pid="z60C7Kx2Dy" dmcf-ptype="figure">
 <img alt="Celltrion CI (Source: Celltrion)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202611/12/Edaily/20261112094119332ybxk.jpg" data-org-width="800" dmcf-mid="u49H4xgRwY" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202611/12/Edaily/20261112094119332ybxk.jpg" width="658">
 <figcaption class="txt_caption default_figure">
 Celltrion CI (Source: Celltrion)
 </figcaption>
 </figure>
 [Kim Saemi, Edaily Reporter] Celltrion announced on November 12 that it has submitted an application to Australia's Therapeutic Goods Administration (TGA) for marketing authorization of Besequma (development code: CT-P55), its proposed biosimilar to Novartis' autoimmune disease treatment Cosentyx (secukinumab).
 The application covers all indications approved for the reference product in Australia, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis.
 Celltrion previously conducted a clinical study involving 172 healthy adults, demonstrating pharmacokinetic (PK) equivalence between Besequma and the reference product. The study also showed comparable safety and immunogenicity profiles.
 The company began its global regulatory submissions in Canada in May, followed by South Korea in June and the United States and Europe in July. With the latest filing in Australia, Celltrion has expanded its regulatory footprint across North America, Europe, Asia and Oceania.
 Besequma is a proposed biosimilar to Cosentyx, an interleukin-17A (IL-17A) inhibitor developed by Novartis for the treatment of autoimmune diseases. Cosentyx generated approximately $6.67 billion (9.3 trillion won) in global sales in 2025, making it a major blockbuster drug.
 Celltrion aims to strengthen its autoimmune disease portfolio through the commercialization of Besequma. The company currently markets several biosimilars in this therapeutic area, including Remsima, Remsima SC (marketed as Zymfentra in the US), Yuflyma, Steqeyma and Avtozma. The launch of Besequma would expand its presence into the IL-17A inhibitor market.
 Australia is an established market for Celltrion, where the company has built a commercial presence through its existing autoimmune disease treatments. Celltrion plans to leverage its local sales experience and distribution network to support Besequma's market entry.
 “Besequma is accelerating its global expansion with regulatory submissions in Australia following the US, Europe and South Korea,” a Celltrion official said. “We will continue expanding our regulatory filings to strengthen the growth momentum of our biosimilar business.”
 Meanwhile, Celltrion plans to expand its commercialized biosimilar portfolio from 11 products to 18 by 2030.
 In the autoimmune disease segment, the company is developing CT-P53, a proposed biosimilar to Ocrevus, and CT-P52, a proposed biosimilar to Taltz. Its oncology pipeline also includes CT-P51, a proposed biosimilar to Keytruda, and CT-P44, a proposed biosimilar to Darzalex.
 김새미 (bird@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기